Key clinical point: The presence of myosteatosis along with increased systemic inflammatory response markers, such as neutrophil-to-lymphocyte ratio (NLR), serves as an independent prognostic indicator in patients with resectable gastric cancer.
Major finding: Co-occurrence of myosteatosis and an NLR of > 2.3 was significantly associated with worse disease-free survival (hazard ratio [HR] 2.77; P = .001) and overall survival (HR 3.31; P < .001).
Study details: This single-center retrospective observational study included 280 patients with gastric cancer who underwent total or partial gastrectomy with curative intent.
Disclosures: This study was funded by Fundação de Amparo à Pesquisa do Estado de São Paulo and Conselho Nacional de Desenvolvimento Científico e Tecnológico, Brazil. The authors declared no conflicts of interest.
Source: Lascala F et al. Prognostic value of myosteatosis and systemic inflammation in patients with resectable gastric cancer: A retrospective study. Eur J Clin Nutr. 2022 (Sep 8). Doi: 10.1038/s41430-022-01201-7